Since the tests that are normally used to evaluate coagulation balances are centered on the procoagulant abnormalities, they do not show this "rebalance" and should be not considered useful tools for the prediction of bleeding or other thrombotic complications. For this reason they are not appropriate decision making tools for cirrhosis patients. 1. asili S, Raparelli V, Violi F. The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur J Intern Med 2010; 212: 62-4. 2. Tripodi A, Primignani M, Mannucci PM. Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern Emerg Med 2010; 51: 7-12. 3. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 912: 267-75. 5. Tripodi A. The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? No. Eur J Intern Med 2010; 212: 65-9. 6. Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006; 32Suppl 1: 32-8. 7. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 278: 1687-93. 9. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis 1996; 74: 459-64. 10. Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999; 191:170-7. 13. Crawley JT, Zanardelli S, Chion CK, Lane DA. The central role of thrombin in hemostasis. J Thromb Haemost 2007; 5Suppl 1: 95-101. 17. Dahlbäck B, Stenflo J. Regulatory mechanisms in hemostasis: natural anticoagulants. En: Hoffman R, Furie B, Benz Jr. EJ, McGlave P, Silberstein LE, Shattil SJ, editors. Hematology: basic principles and practice. 5 edition. Philadelphia: Churchill, Livingstone: Elsevier; 2009. p. 1843-9. 18. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006; 1248: 7725-36. 19. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007 244: 250-8. 20. Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 445: 754-8. 21. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, et al. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 2003; 376: 1267-76. 22. Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 242: 135-40. 23. Feistauer SM, Penner E, Mayr WR, Panzer S. Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 1997; 256: 1343-5. 26. Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer PFA-100 : influence of hematocrit elevation. Haematologica 1999; 847: 614-9. 27. Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994; 832: 404-14. 28. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 893: 273-93. 29. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 441: 53-61. 32. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 3055: 242-8. 33. Francis JL, ArmB DJ. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease. Haemostasis 1982; 114: 215-22. 34. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 464: 727-33. 35. Leiper K, Croll A, Booth NA, Moore NR, Sinclair T, Bennett B. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. J Clin Pathol 1994; 473: 214-7. 36. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 1211: 131-9. 37. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 381: 230-7. 38. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 372: 280-7. 39. Vukovich T, Teufelsbauer H, Fritzer M, Kreuzer S, Knoflach P. Hemostasis activation in patients with liver cirrhosis. Thromb Res 1995; 773: 271-8. 40. Artiko V, Obradovic V, Petrovic M, Perisic M, Stojkovic M, Sobic-Saranovic D, et al. Hepatic radionuclide angiography and Doppler ultrasonography in the detection and assessment of vascular disturbances in the portal system. Hepatogastroenterology 2007; 5475: 892-7. 41. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 119: 1107-11. 42. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol 2005; 39Suppl 2: S138-42. 43. Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009; 131: 117-26. 44. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 532: 362-71. 45. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 444: 1039-46. 46. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 989: 2730-5. 47. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 413: 553-8. 48. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 1376: 2105-11. 49. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 265: 388-93. 50. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 459: 1413-25. 51. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 61: 79-86. 52. Tellez-Avila FI, Chavez-Tapia NC, Torre-Delgadillo A. [Coagulation disorders in cirrhosis]. Rev Invest Clin 2007; 592: 153-60. 54. Wong AY, Irwin MG, Hui TW, Fung SK, Fan ST, Ma ES. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003; 501: 14-20. 56. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 442: 440-5. 57. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006; 261: 133-9. 58. Lisman T, Adelmeijer J, de Groot PG, Janssen HL, Leebeek FW. No evidence for an intrinsic platelet defect in patients with liver cirrhosis--studies under flow conditions. J Thromb Haemost 2006; 49: 2070-2. 59. Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 493: 238-44. 60. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 332: 464-70. 61. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 412: 353-8. 62. Arjal R, Trotter JF. International normalized ratio of prothrombin time in the model for end-stage liver disease score: an unreliable measure. Clin Liver Dis 2009; 131: 67-71. 63. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, et al. The international normalized ratio calibrated for cirrhosis INRliver normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 462: 520-7. 64. Kovacs MJ, Wong A, MacKinnon K, Weir K, Keeney M, Boyle E, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994; 716: 727-30. 65. Denson KW, Reed SV, Haddon ME, Woodhams B, Brucato C, Ruiz J. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res 1999; 944: 255-61. 66. Robert A, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 246: 1392-4. 67. Kamath PS, Kim WR. The international normalized ratio of prothrombin time in the model for end-stage liver disease score: a reliable measure. Clin Liver Dis 2009; 131: 63-6. 69. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer--PFA-100. Semin Thromb Hemost 1995; 21Suppl 2: 106-12. 70. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 331: 4-15. 71. Chantarangkul V, Clerici M, Bressi C, Giesen PL, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 885: 547-54.
Como las pruebas comúnmente utilizadas para la evaluación del estado de coagulación de estos pacientes no muestran este nuevo rebalance ya que se centran en las alteraciones del componente procoagulante, no deben considerarse herramientas útiles para la predicción del riesgo de sangrado o de complicaciones trombóticas; por ende, no es apropiada la toma de decisiones con base en la alteración de sus resultados.